Details for Patent: 11,033,552

Which drugs does patent 11,033,552 protect, and when does it expire?

Patent 11,033,552 protects GLYXAMBI and TRADJENTA and is included in two NDAs.

Protection for GLYXAMBI has been extended six months for pediatric studies, as indicated by the *PED designation in the table below.

This patent has ninety patent family members in thirty-six countries.

Summary for Patent: 11,033,552

Title:	DPP IV inhibitor formulations
Abstract:	The present invention relates to pharmaceutical compositions of DPP IV inhibitors with an amino group, their preparation and their use to treat diabetes mellitus.
Inventor(s):	Anja Kohlrausch, Patrick Romer, Gerd Seiffert
Assignee:	Boehringer Ingelheim International GmbH
Application Number:	US16/357,357
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 11,033,552
Patent Claim Types: see list of patent claims	Composition; Compound; Dosage form;

Drugs Protected by US Patent 11,033,552

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Boehringer Ingelheim	GLYXAMBI	empagliflozin; linagliptin	TABLET;ORAL	206073-001	Jan 30, 2015		RX	Yes	No	11,033,552*PED				Y
Boehringer Ingelheim	GLYXAMBI	empagliflozin; linagliptin	TABLET;ORAL	206073-002	Jan 30, 2015		RX	Yes	Yes	11,033,552*PED				Y
Boehringer Ingelheim	TRADJENTA	linagliptin	TABLET;ORAL	201280-001	May 2, 2011	AB	RX	Yes	Yes	11,033,552*PED				Y

Foreign Priority and PCT Information for Patent: 11,033,552

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
	06009201	May 4, 2006

International Family Members for US Patent 11,033,552

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Argentina	060755
Argentina	079930
Austria	E480228